HEMOSTEMIX INC.
Raise of up to $2,500,000
The Offering:
Up to 50,000,000 Units
Each Unit priced at $0.05
Each Unit consists of one common share (a “Share”) and one common share purchase warrant (a “Warrant”). Each warrant may be exercised at a price of $0.12 for a period of two years, subject to the accelerator described as follows: If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the Closing Date, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the Exchange is greater than a weighted average price of $0.15 per common share, the Company may provide notice in writing to the holders of the warrants by issuance of a press release that the expiry date of the warrants will be accelerated to the 30th day after the date on which the Company issues such press release
Minimum order: $5,000
Securities issued under this offering will be subject to the statutory four month plus one day hold period
The offering is available to investors utilizing the accredited investor exemption
The offering is RRSP/TFSA eligible
About Hemostemix Inc.:
Hemostemix Inc. (TSXV: HEM; OTCQB:HMTXF) (“Hemostemix” or the “Company”) is an autologous (patient’s own) stem cell company with a promising break through treatment for ischemia (ischemic cardiomyopathy, angina, peripheral arterial disease including chronic limb threatening ischemia (“CLTI”)).
Hemostemix’s patented technology is based on more than 15 years of clinical data demonstrating the ability of our patient’s cell product to regenerate diseased and damaged ischemic tissue and organs.
The Company’s cost-effective manufacturing platform is designed to generate up to 240 therapeutic batches ($12 Million) per month from one manufacturing cell and scale by 240 treatments with each additional manufacturing cell.
ACP-01 (“ACP”), our lead clinical stage candidate, like NCP-01 and CCP-01, is generated from the patient’s own blood with a short production time.
Exchange: TSXV
Symbol: HEM
Current Share Price: $0.09 (Nov 26, 2024)
Use of Proceeds:
Proceeds from the Offering will be used to initiate sales and the processing of initial batches in 2024 and for general working capital purposes.
Corporate Structure:
Investment Highlights:
ACP is a break-through treatment for no-option angina, dilated and ischemic cardiomyopathy and CLTI.
ACP is effective, and, because it is sourced from the patient's own blood and cultured in the patient's serum, it is completely autologous and therefore safe in the short and long term.
ACP is protected by 91 patents and is globally scalable. The production team has more than 20 years of stem cell experience.
Published three studies, each in a peer reviewed journal, which indicated improved heart function by up to 27%.
Saved 93.5% of limbs from amputation in phase II trial.
498 patients treated, 7 studies, including a phase II trial, demonstrate ACP is safe and effective.
Over $40 million invested in technology over 15 years of development (management and board have invested $8.75 million).
The Company has filed for orphan disease status for Dilated Cardiomyopathy. Once status is granted, it provides 7 years exclusivity, fee abatement, and grant funding opportunities.
ACP addresses two very large markets that are comprised of significant unmet needs
Canadian Institute of Health Information (““CIHI”) estimates that hospitalizations related to CLTI amputation account for over $750 million in health-care costs per year in Canada - Click here to read the September 28, 2024 National Post article discussing the CIHI Report
In August 2024, Hemostemix signed a binding and definitive Manufacturing Services Agreement with CytoImmune Therapuetics (“CytoImmune”) that re-establishes production of ACP-01 at CytoImmune’s state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico. This Agreement provides the Company with a renewable two-year fixed cost, high margin, product to sell globally.
ACT 60 (Puerto Rico legislation) generates 50% cash back of all R&D, a 15-year 4% profit tax, and a 20% tax credit for offshore expenses.
Significant revenue at high margin (up to 80+%) from scalable compassionate treatments in 2025 and clinical trials
The Company expects to be cashflow positive by late 2025.
Ascenta Offerings are available on a ‘first-come, first-served’ basis. Please express your interest in participating in this financing and we will attempt to hold a position for you. Once you have been confirmed, we will provide you with a Subscription Agreement and Ascenta’s Know Your Client information.
Closingof the Private Placement Financing will occur at the Company’s discretion.
Members of Ascenta may invest alongside its network in this offering.
Closings of this financing will occur at the Company’s discretion.
The Company has agreed to pay a finder’s fee of 8% cash and 8% warrants for the private placement financing.